Vir Biotech Insider Sale: 22,000 Shares Sold Under 10b5-1 Plan
Rhea-AI Filing Summary
Vicki L. Sato, a director of Vir Biotechnology, Inc. (VIR), sold 22,000 shares on 09/02/2025 under a Rule 10b5-1 trading plan adopted March 27, 2025. The reported weighted-average sale price was $4.9914, with individual sale prices ranging from $4.88 to $5.07. After the reported sales, the filing shows 1,254,391 shares beneficially owned by the reporting person. The Form 4 was signed by an attorney-in-fact on 09/03/2025 and discloses that full breakdowns of shares sold at each price are available upon request.
Positive
- Sale executed under a documented Rule 10b5-1 trading plan, which enhances compliance transparency
- Reporting person retains a substantial holding after the sale (1,254,391 shares)
Negative
- Disposition of 22,000 shares reduces the reporting persons direct stake
- Sale executed at market prices (weighted avg $4.9914; range $4.88 $5.07), which may modestly increase share supply near those price levels
Insights
TL;DR: Insider sale executed under a documented 10b5-1 plan reduces appearance of opportunistic trading.
The filing shows a routine disposition by a company director using a pre-established Rule 10b5-1 plan, which is a commonly used compliance mechanism to mitigate questions about insider timing. The sale size (22,000 shares) should be evaluated relative to the director's remaining position of 1,254,391 shares; here the sale represents a small fraction of total holdings, suggesting no change in control or material shift in alignment with shareholders. The disclosure of the price range and undertaking to provide per-price breakdowns is appropriate and improves transparency.
TL;DR: Transaction is a disclosed insider liquidation under plan terms, with limited immediate market impact.
The weighted-average price of $4.9914 and the disclosed price range ($4.88–$5.07) indicate executions over multiple trades rather than a single block trade. The remaining beneficial ownership of 1.25 million shares retains substantial insider exposure. There is no indication of derivative transactions or amendments to prior filings in this Form 4. For investors, the material facts are the use of a 10b5-1 plan and the modest scale of the sale versus total holdings.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 22,000 | $4.9914 | $110K |
Footnotes (1)
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.88 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
